Cancer Chemotherapy and Pharmacology

, Volume 7, Issue 2–3, pp 133–140 | Cite as

The clinical pharmacology of VM26 and VP16-213

A brief overview
  • Patrick J. Creaven
Articles VP16-213 Clinical Pharmacology


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Allen LM (1978) The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM26. Drug Metab Rev 8:119Google Scholar
  2. 2.
    Allen LM (1978) Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4′-demethyl epipodophyllotoxin thenylidene-β-d-glucoside and 4′-demethyl epipodophyllotoxin ethylidene-β-d-glucoside in the L1210 leukemia cell. Cancer Res 38:2549Google Scholar
  3. 3.
    Allen LM (1980) Analysis of 4′-demethyl epipodophyllotoxin-9-(4,6-O-ethylidene-β-d-glucopyranoside) by high-pressure liquid chromatography. J Pharm Sci 69:1440Google Scholar
  4. 4.
    Allen LM, Creaven PJ (1975) Comparison of the human pharmacokinetics of VM26 and VP16-213, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur J Cancer 11:697Google Scholar
  5. 5.
    Allen LM, Marcks C, Creaven PJ (1976) 4′-Demethyl-epipodophyllic acid-9-(4,6-O-ethylidene-β-d-glucopyranoside), the major urinary metabolite of VP16-213 in man. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 17:6Google Scholar
  6. 6.
    Arnold AM (1979) Podophyllotoxin derivative VP16-213. Cancer Chemother Pharmacol 3:71Google Scholar
  7. 7.
    Arnold AM, Dodson M, Renwick A, Whitehouse JMA (1980) Pharmacokinetics of VP16-213 using a new HPLC assay. Cancer Chemother Pharmacol (Suppl) 5:2Google Scholar
  8. 8.
    Bleyer WA, Krivit W, Chard RL Jr, Hammond D (1979) Phase II study of VM26 in acute leukemia, neuroblastoma and other refractory childhood malignancies: A report from the children's cancer study group. Cancer Treat Rep 63:977Google Scholar
  9. 9.
    Brunner KW, Sonntag RW, Ryssel HJ, Cavalli F (1976) Comparison of the biologic activity of VP16-213 given IV and orally in capsules or drink ampules. Cancer Treat Rep 60:1377Google Scholar
  10. 10.
    Cavalli F, Sonntag RW, Jungi F, Senn HJ, Brunner KW (1978) VP16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62:473Google Scholar
  11. 11.
    Creaven PJ, Allen LM (1975) EPEG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 18:221Google Scholar
  12. 12.
    Creaven PJ, Allen LM (1975) PTG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 18:227Google Scholar
  13. 14.
    Creaven PJ, Newman SJ, Selawry OS, Cohen MH, Primack A (1974) Phase I clinical trial of weekly administration of 4′-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-d-glucopyranoside) (NSC 141540; VP16-213). Cancer Chemother Rep 58:901Google Scholar
  14. 15.
    D'Incalci M, Farina P, Fasoli M, Marsoni S (1981) VP16-213 plasma levels after I.V. and two methods of oral administration to choriocarcinoma patients. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 22:357Google Scholar
  15. 16.
    Evans WE, Sinkule JA, Horvath A, Crom WR, Dow LW, Rivera G (1981) Clinical pharmacology of VM26 (NSC 122819) and VP16-213 (NSC 141540) in children with cancer. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 22:174Google Scholar
  16. 17.
    Falkson G, Van Dyk JJ, Van Eden EB, Van Der Merwe AM, Van Den Bergh JA, Falkson HC (1975) A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-d-ethylidene glucoside (NSC 141540) VP16-213. Cancer 35:1141Google Scholar
  17. 18.
    Farina P, Marzillo G, D'Incalci M (1981) High-performance liquid chromatography determination of 4′-demethyl-epipo-dophyllotoxin-9-(4,6-O-ethylidene-β-d-glucopyranoside) (VP16-213) in human plasma. J Chromatogr 222:141Google Scholar
  18. 19.
    Goldsmith MA, Carter SK (1973) 4′-Demethyl-epipodophyllotoxin-β-d-thenylidene glucoside (VM26). A brief review. Eur J Cancer 9:477Google Scholar
  19. 20.
    Issell BF, Crooke ST (1979) Etoposide (VP16-213). Cancer Treat Rev 6:107Google Scholar
  20. 21.
    Knott GD, Reece DK (1972) MLAB: a civilized curve-fitting system. Proc On-Line 1:497Google Scholar
  21. 22.
    Lau ME, Hansen HH, Nissen NI, Pedersen H (1979) Phase I trial of a new form of an oral administration of VP16-213. Cancer Treat Rep 63:485Google Scholar
  22. 23.
    Madajewicz S, West CR, Park HC, Avellanosa AM, Caracandas JE, Takita H, Vicent RG, Jennings E (1981) Phase II study of intra-arterial 4-0-demethyl-1-0-(4,6-O-2-thenylidene-β-d-glucopyranosyl) epipodophyllotoxin (VM26) therapy of metastatic bronchogenic adenocarcinoma to the brain. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 22:502Google Scholar
  23. 24.
    Metzler CM (1969) NONLIN, Tech Rep No 7292/69-7293/005 Upjohn, MichiganGoogle Scholar
  24. 25.
    Muggia FM, Selawry OS, Hansen HH (1971) Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4′-demethyl-9-(4,6-O-2-thenylidene-β-d-glucopyranoside) (NSC 122819). Cancer Chemother Rep 55:575Google Scholar
  25. 26.
    Nissen NI, Dombernowsky P, Hansen HH, Larsen V (1976) Phase I clinical trial of an oral solution of VP16-213. Cancer Treat Rep 60:943Google Scholar
  26. 27.
    Nissen NI, Hansen HH, Pedersen H, Stroyer I, Dombernowsky P, Hessellund M (1975) Clinical trial of the oral form of a new podophyllotoxin derivative, VP16-213 (NSC 141540), in patients with advanced neoplastic disease. Cancer Chemother Rep 59:1027Google Scholar
  27. 28.
    Nissen NI, Larsen V, Pedersen H, Thomsen K (1972) Phase I clinical trial of a new antitumor agent, 4′-demethylepipodo-phyllotoxin 9-(4,6-O-ethylidene-β-d-glucopyranoside) (NSC 141540; VP16-213). Cancer Chemother Rep 56:769Google Scholar
  28. 29.
    Pelsor FR, Allen LM, Creaven PJ (1978) Multicompartment pharmacokinetic model of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-β-d-glucopyranoside) in humans. J Pharm Sci 67:1106Google Scholar
  29. 30.
    Radice PA, Bunn PA, Ihde DC (1979) Therapeutic trials with VP16-213 and VM26: Active agents in small cell lung cancer, non-Hodgkins lymphomas and other malignancies. Cancer Treat Rep 63:1231Google Scholar
  30. 31.
    Rozencweig M, Von Hoff DD, Henney JE, Muggia FM (1977) VM26 and VP16-213. A comparatve analysis. Cancer 40:334Google Scholar
  31. 32.
    Sandoz Pharmaceuticals, Preclinical Brochure (1967) VM26. Research Department, Hanover New JerseyGoogle Scholar
  32. 33.
    Sandoz Pharmaceuticals, Preclinical Brochure (1971) VP16-213. Research Department, Hanover New JerseyGoogle Scholar
  33. 34.
    Snodgrass W, Walker L, Heideman R, Odom LF, Hays T, Tubergen DG (1980) Kinetics of VP16-213 epipodophyllotoxin in children with cancer. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 21:333Google Scholar
  34. 35.
    Spremulli E, Schulz JJ, Speckhart VJ, Wampler GL (1980) Phase II study of VM26 in adult malignancies. Cancer Treat Rep 64:147Google Scholar
  35. 36.
    Strife RJ, Jardine I, Colvin M (1980) Analysis of the anticancer drugs VP16-213 and VM26 and their metabolites by high performance liquid chromatography. J Chromatogr 182:211Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • Patrick J. Creaven
    • 1
  1. 1.Department of Clinical Pharmacology and Therapeutics, Roswell Park Memorial InstituteNew York State Department of HealthBuffaloUSA

Personalised recommendations